Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck stock has slipped this year amid the coronavirus pandemic. But the pharmaceutical company is pursuing two coronavirus vaccines.

Merck Is Now Pursuing Two Coronavirus Vaccines — Is Merck Stock A Buy?

Johnson & Johnson

Johnson & Johnson’s stock has gained 38% since the March 23 lows of this year, while Merck’s stock has slightly underperformed and gained 30% of its value. The lockdown in various parts of the world has had a negative impact on the pharmaceuticals industry worldwide due to deferment of elective.

Merck Vs JNJ, Merck's Got More Magic

Shares of catalyst-rich pharma Merck & Co., Inc. (NYSE: MRK) are poised for further upside, according to an analyst at SVB Leerink.

Merck Analyst Raises Price Target Ahead Of Upcoming Antiviral Trial Results, Presentation

Merck's (MRK) Keytruda receives approval in Japan as second-line treatment for esophageal squamous cell carcinoma. A new dosing regimen also receives approval in the country.

Merck's Keytruda Gets Approval for Esophageal Cancer in Japan

Apple

Disney

NIKE

Procter & Gamble

The Dow Jones Industrial Index ended above 28,000 for the first time in six months.

Dow Reclaims 28,000: 5 Stocks Driving the ETF Rally

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan

Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan

Aldeyra Therapeutics

ChromaDex

Chevron

Home Depot

Intel

Nuveen Quality Municipal Income Fund

Verizon

Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Merck's (MRK) Keytruda improves overall survival and progression-free survival compared to current standard of care in first-line metastatic esophageal cancer patients.

Merck's Keytruda Positive in First-Line Esophageal Cancer Study

AstraZeneca

BioNTech SE

Moderna

Pfizer

What’s the best way for investors to gain diversified exposure to today's leading vaccine research? Here he recommends a 5-stock portfolio to boost your chances to benefit from potential progress made toward a successful Covid vaccine.

This 5-Stock Portfolio Is A Safe Bet On A Future COVID-19 Vaccine

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA® in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival in Esophageal Cancer

Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer

Eli Lilly

Only one of these stocks has performed well this year, but both are worth buying and holding over the long term.

2 Forever Pharma Stocks to Buy Now

AbbVie

Novartis

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

Inovio Pharmaceuticals

Novavax

COVID-19 has weakened the US economy more than China's.

T Cell Responses To Coronavirus Vaccines Are In The Interest Of National Security

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Novo Nordisk

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

The biotech sector had a troubled Q2, as doctor visits were curtailed and new Rx'es were in short supply; R&D efforts were also harmed.

Biotech's Q2:  Lots Of Candidates That May Deliver Alpha

Merck KGaA (MKGAF) CEO Stefan Oschmann on Q2 2020 Results - Earnings Call Transcript

Automatic Data Processing

Cisco Systems

General Dynamics

ONEOK

Parker-Hannifin

Prudential Financial

Wells Fargo

This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe, dividend-paying, and are offering large discounts to their historical norms.

5 Safe And Cheap Dividend Stocks To Invest In (August 2020)

eBay

Scotts Miracle-Gro

Whether you're looking for growth or dividend income, these stocks could be great additions to your portfolio.

3 Companies That Raised Their Guidance Amid the Coronavirus Pandemic

The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.

NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment

Biotech stocks are on fire at the moment. That said, here are five names from the sector that offer long-term value and strong fundamentals.

5 Biotech Stocks That Offer Long-Term Growth and Value

Many people are putting off vaccinations for diseases they view as less threatening than the coronavirus.

Pfizer, Merck, and Others See a Slowdown in Vaccine Sales, but Anticipate an Autumn Rebound

MRK stock isn't bad. It has a reasonable valuation, okay growth and a solid dividend.

Merck Stock Remains a Dull Biotech Play Despite Earnings Success

Alexion Pharma

Royalty Pharma

The biopharmaceutical industry has been one of the most resilient in dealing with the coronavirus pandemic.

5 Large Biotechs and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-19

MADISON, N.J.--(BUSINESS WIRE)---- $MRK #AnimalHealth--Merck Animal Health Completes Acquisition of IdentiGEN

Merck Animal Health Completes Acquisition of IdentiGEN

Massive sales from the ever-so dependable Keytruda in the second quarter and aggressive actions make MRK stock a fabulous investment.

Keytruda Powers a Stellar Q2 for Merck

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for NASH

Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)

News for Merck Stock (MRK)